Patents by Inventor Benyamin YAZDAN PANAH
Benyamin YAZDAN PANAH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240246056Abstract: The present invention relates to a manufacturing device for a pharmaceutical product, a manufacturing module for a pharmaceutical product, a manufacturing system for a pharmaceutical product, a method for producing a pharmaceutical product, a method for producing a DNA template, a method for producing an RNA, a method for producing a formulated RNA and uses of the manufacturing device, module or system. The manufacturing device for a pharmaceutical product comprises a housing, a process chamber, a technical chamber, a separation element, and a control unit. The housing is closed relative to the environment outside the housing. The housing encompasses the process chamber and the technical chamber. The process chamber is separated from the technical chamber by the separation element. The control unit is configured to control a gas flow through the process chamber. The control unit is configured to control the gas flow to provide in the process chamber a positive pressure relative to the environment.Type: ApplicationFiled: September 1, 2021Publication date: July 25, 2024Applicants: CureVac RNA Printer GmbH, Tesla Automation GmbHInventors: Benyamin YAZDAN PANAH, Tilmann ROOS, Telmo GRACA, Felix BERTSCH, Veronika FONTIUS, Michael RAUEN, Nico SCHOLTES, Philipp HOFFMANN, Martin KUNZE
-
Publication number: 20240100142Abstract: The invention relates to a method for producing a ribonucleic acid (RNA) molecule composition comprising n different RNA molecule species, the method comprising a step of RNA in vitro transcription of a mixture of m different deoxyribonucleic acid (DNA) molecule species in a single reaction vessel in parallel, i.e. simultaneously, and a step of obtaining the RNA molecule composition. Also provided is the RNA composition provided by the inventive method and a pharmaceutical composition comprising the same as well as a pharmaceutical container. Moreover, the invention provides the RNA composition and the pharmaceutical composition for use as medicament.Type: ApplicationFiled: May 11, 2023Publication date: March 28, 2024Applicant: CureVac SEInventors: Tilmann ROOS, Martin KUNZE, Benyamin YAZDAN PANAH, Salih YILMAZ, Markus CONZELMANN
-
Publication number: 20230295709Abstract: The present invention is concerned with linear double stranded DNA, which is coupled to a single support or a tag at the 3? end of its non-coding strand and methods for producing said linear double stranded DNA. The present invention further relates to the use of said linear double stranded DNA in an RNA in vitro transcription reaction and also to a method for producing RNA in vitro. The present invention also relates to a bioreactor for RNA in vitro transcription.Type: ApplicationFiled: November 22, 2022Publication date: September 21, 2023Applicant: CureVac SEInventors: Benyamin YAZDAN PANAH, Tilmann ROOS, Veronika WAGNER, Carola PONGRATZ
-
Publication number: 20230227881Abstract: The present invention relates to an immobilized capping enzyme, preferably an immobilized Vaccinia virus capping enzyme. Furthermore, the present invention relates to an immobilized cap-specific nucleoside 2?-O-methyltransferase, preferably an immobilized Vaccinia virus cap-specific nucleoside 2?-O-methyltransferase. Moreover, the present invention relates to a method for immobilizing said enzymes and to a method of using said enzymes for the addition of a 5?-cap structure to RNAs. Moreover, the present invention relates to an enzyme reactor for performing the capping reaction using said immobilized enzymes and the subsequent separation of the 5?-capped RNA product. In addition, the present invention relates to a kit comprising the capping enzyme and/or the cap-specific nucleoside 2?-O-methyltransferase.Type: ApplicationFiled: January 13, 2023Publication date: July 20, 2023Applicant: CureVac SEInventors: Tilmann ROOS, Benyamin YAZDAN PANAH, Markus CONZELMANN, Andreas THESS, Dominik BUOB, Martin KUNZE, Veronika WAGNER
-
Patent number: 11684665Abstract: The invention relates to a method for producing a ribonucleic acid (RNA) molecule composition comprising n different RNA molecule species, the method comprising a step of RNA in vitro transcription of a mixture of m different deoxyribonucleic acid (DNA) molecule species in a single reaction vessel in parallel, i.e. simultaneously, and a step of obtaining the RNA molecule composition. Also provided is the RNA composition provided by the inventive method and a pharmaceutical composition comprising the same as well as a pharmaceutical container. Moreover, the invention provides the RNA composition and the pharmaceutical composition for use as medicament.Type: GrantFiled: December 22, 2016Date of Patent: June 27, 2023Assignee: CureVac SEInventors: Tilmann Roos, Martin Kunze, Benyamin Yazdan Panah, Salih Yilmaz, Markus Conzelmann
-
Patent number: 11608513Abstract: The present invention relates to an immobilized capping enzyme, preferably an immobilized Vaccinia virus capping enzyme. Furthermore, the present invention relates to an immobilized cap-specific nucleoside 2?-O-methyltransferase, preferably an immobilized Vaccinia virus cap-specific nucleoside 2?-O-methyltransferase. Moreover, the present invention relates to a method for immobilizing said enzymes and to a method of using said enzymes for the addition of a 5?-cap structure to RNAs. Moreover, the present invention relates to an enzyme reactor for performing the capping reaction using said immobilized enzymes and the subsequent separation of the 5?-capped RNA product. In addition, the present invention relates to a kit comprising the capping enzyme and/or the cap-specific nucleoside 2?-O-methyltransferase.Type: GrantFiled: May 30, 2016Date of Patent: March 21, 2023Assignee: CureVac SEInventors: Tilmann Roos, Benyamin Yazdan Panah, Markus Conzelmann, Andreas Thess, Dominik Buob, Martin Kunze, Veronika Wagner
-
Patent number: 11534405Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-freeze drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.Type: GrantFiled: June 18, 2020Date of Patent: December 27, 2022Assignee: CureVac AGInventors: Fabian Johannes Eber, Benyamin Yazdan Panah, Stefanie Sewing, Thomas Ketterer, Thorsten Mutzke, Tilmann Roos, Michael Sonntag, Michael Wiggenhorn, Katharina Kolland
-
Patent number: 11525158Abstract: The present invention is concerned with linear double stranded DNA, which is coupled to a single support or a tag at the 3? end of its non-coding strand and methods for producing said linear double stranded DNA. The present invention further relates to the use of said linear double stranded DNA in an RNA in vitro transcription reaction and also to a method for producing RNA in vitro. The present invention also relates to a bioreactor for RNA in vitro transcription.Type: GrantFiled: December 21, 2018Date of Patent: December 13, 2022Assignee: CureVac SEInventors: Benyamin Yazdan Panah, Tilmann Roos, Veronika Wagner, Carola Pongratz
-
Publication number: 20220387320Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.Type: ApplicationFiled: July 11, 2022Publication date: December 8, 2022Applicant: CureVac AGInventors: Fabian Johannes EBER, Benyamin YAZDAN PANAH, Stefanie SEWING, Thomas KETTERER, Thorsten MUTZKE, Tilmann ROOS, Michael SONNTAG, Michael WIGGENHORN, Katharina KOLLAND
-
Publication number: 20220389470Abstract: The present invention relates to a method for in vitro transcription of a linear template DNA which is produced using an immobilized restriction endonuclease. The invention also relates to mutated restriction enzymes which are suitable for immobilization and a solid support to which these restriction enzymes are immobilized. Further, the present invention relates to an enzyme reactor containing said immobilized restriction endonuclease which enzyme reactor can be used for preparing linearized template DNA. Finally, the present invention relates to the use of said enzyme reactor for preparing a linear template DNA for in vitro transcription. In addition, the present invention relates to a kit comprising the immobilized restriction endonuclease.Type: ApplicationFiled: August 17, 2022Publication date: December 8, 2022Applicant: CureVac AGInventors: Tilmann ROOS, Benyamin YAZDAN PANAH, Martin KUNZE
-
Publication number: 20220348976Abstract: The present invention relates to an immobilized poly(N)polymerase (PNP), methods of producing said PNP and uses thereof. Further disclosed is an enzyme reactor and kit comprising the PNP for producing polynucleotidylated ribonucleic acid (poly(N)RNA) molecules which are useful in gene therapy, immunotherapy, protein replacement therapy and/or vaccination.Type: ApplicationFiled: June 13, 2022Publication date: November 3, 2022Applicant: CureVac AGInventors: Tilmann ROOS, Benyamin YAZDAN PANAH, Markus CONZELMANN, Veronika WAGNER
-
Patent number: 11433027Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.Type: GrantFiled: August 20, 2020Date of Patent: September 6, 2022Assignee: CureVac AGInventors: Fabian Johannes Eber, Benyamin Yazdan Panah, Stefanie Sewing, Thomas Ketterer, Thorsten Mutzke, Tilmann Roos, Michael Sonntag, Michael Wiggenhorn, Katharina Kolland
-
Patent number: 11384375Abstract: The present invention relates to an immobilized poly(N)polymerase (PNP), methods of producing said PNP and uses thereof. Further disclosed is an enzyme reactor and kit comprising the PNP for producing polynucleotidylated ribonucleic acid poly(N)RNA)molecules which are useful in gene therapy, immunotherapy, protein replacement therapy and/or vaccination.Type: GrantFiled: May 2, 2016Date of Patent: July 12, 2022Assignee: CureVac AGInventors: Tilmann Roos, Benyamin Yazdan Panah, Markus Conzelmann, Veronika Wagner
-
Publication number: 20220168225Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-freeze drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.Type: ApplicationFiled: February 21, 2022Publication date: June 2, 2022Applicant: CureVac AGInventors: Fabian Johannes EBER, Benyamin YAZDAN PANAH, Stefanie SEWING, Thomas KETTERER, Thorsten MUTZKE, Tilmann ROOS, Michael SONNTAG, Michael WIGGENHORN, Katharina KOLLAND
-
Publication number: 20220119795Abstract: The present invention relates to a buffer system comprising a dicarboxylic acid or tricarboxylic acid or a salt thereof for synthesizing RNA molecules as well as a method of RNA in vitro transcription using this buffer system. The present invention also provides the use of this buffer system in RNA in vitro transcription and in the reduction or prevention of precipitates during RNA in vitro transcription.Type: ApplicationFiled: January 3, 2022Publication date: April 21, 2022Applicant: CureVac AGInventors: Benyamin YAZDAN PANAH, Aniela WOCHNER, Tilmann ROOS, Andreas FUNKNER, Martin KUNZE
-
Publication number: 20220073962Abstract: The present invention is concerned with methods for analyzing RNA molecules. The provided methods involve conjugates for RNA cleavage comprising a chemical moiety with RNA cleaving activity and an oligonucleotide. The oligonucleotide is designed based on a target sequence present in an RNA molecule, and the cleavage of the RNA molecule is inter alia carried out at conditions allowing the hybridization of the oligonucleotide to the target 5 sequence. Thereby, the method is easily applicable to RNA molecules of any sequence. The method further involves the analysis of the RNA fragments obtained after cleavage to obtain information on the physical properties of the RNA molecule.Type: ApplicationFiled: December 20, 2019Publication date: March 10, 2022Applicant: CureVac AGInventors: Alexander SCHWENGER, Stefan HEINZ, Tilmann ROOS, Benyamin YAZDAN PANAH, Veronika WAGNER
-
Patent number: 11248223Abstract: The present invention relates to a buffer system comprising a dicarboxylic acid or tricarboxylic acid or a salt thereof for synthesizing RNA molecules as well as a method of RNA in vitro transcription using this buffer system. The present invention also provides the use of this buffer system in RNA in vitro transcription and in the reduction or prevention of precipitates during RNA in vitro transcription.Type: GrantFiled: December 23, 2016Date of Patent: February 15, 2022Assignee: CureVac AGInventors: Benyamin Yazdan Panah, Aniela Wochner, Tilmann Roos, Andreas Funkner, Martin Kunze
-
Patent number: 11179337Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.Type: GrantFiled: November 11, 2019Date of Patent: November 23, 2021Assignee: CureVac AGInventors: Fabian Johannes Eber, Benyamin Yazdan Panah, Stefanie Sewing, Thomas Ketterer, Thorsten Mutzke, Tilmann Roos, Michael Sonntag, Michael Wiggenhorn, Katharina Kolland
-
Publication number: 20210261897Abstract: The present invention relates to a bioreactor for RNA in vitro transcription, a method for RNA in vitro transcription, a module for transcribing DNA into RNA and an automated apparatus for RNA manufacturing. Further, the use of a bioreactor for RNA in vitro transcription as described herein is part of the present invention. The present invention relates to an RNA in vitro transcription reactor designed to be operable in an automated manner under GMP-compliant conditions. In particular, said RNA in vitro transcription reactor allows repetitive use of DNA template for various RNA in vitro transcription reactions. Further, the invention relates to an apparatus for RNA manufacturing comprising (a) a module for template DNA synthesis, (b) a module for transcribing DNA into RNA comprising said RNA in vitro transcription reactor, and, optionally, (c) a module for RNA formulation.Type: ApplicationFiled: June 28, 2019Publication date: August 26, 2021Applicants: CureVac AG, Tesla Grohmann Automation GmbHInventors: Benyamin YAZDAN PANAH, Tilmann ROOS, Martin KUNZE, Felix BERTSCH, Aniela WOCHNER, Michael RAUEN, Philipp HOFFMANN
-
Publication number: 20210030683Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-freeze drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.Type: ApplicationFiled: June 18, 2020Publication date: February 4, 2021Applicant: CureVac AGInventors: Fabian Johannes EBER, Benyamin YAZDAN PANAH, Stefanie SEWING, Thomas KETTERER, Thorsten MUTZKE, Tilmann ROOS, Michael SONNTAG, Michael WIGGENHORN, Katharina KOLLAND